Literature DB >> 9806032

Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais.

J A Lynch1, M deSouza, M D Robb, L Markowitz, S Nitayaphan, C V Sapan, D L Mann, D L Birx, J H Cox.   

Abstract

A globally effective vaccine will need to elicit cytotoxic T lymphocytes (CTL) capable of recognizing diverse human immunodeficiency virus type 1 (HIV-1) clades. Study of the cellular immune responses of HIV-1-infected persons may allow predictions to be made regarding useful vaccine antigen components. The frequency and magnitude of CTL responses to clade E and B Gag, Pol-RT, Env, and Nef proteins were compared in 12 HLA-characterized, clade E-infected Thais and in 10 clade B-infected North Americans using vaccinia recombinant constructs for protein expression. While responses were detected against all proteins, they were most frequent and cross-reactive to Gag in both groups. Pol-RT was recognized less frequently in Thais than North Americans. Cross-clade protein recognition was common but not uniformly present among these HLA-disparate individuals. Population-specific CTL data are needed to adequately prepare for vaccine trials outside of North America and Europe.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806032     DOI: 10.1086/515652

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Authors:  Philip J Norris; Howell F Moffett; Christian Brander; Todd M Allen; Kristin M O'Sullivan; Lisa A Cosimi; Daniel E Kaufmann; Bruce D Walker; Eric S Rosenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2004-03       Impact factor: 2.205

2.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Patient-specific cytotoxic T-lymphocyte cross-recognition of naturally occurring variants of a human immunodeficiency virus type 1 (HIV-1) p24gag epitope by HIV-1-infected children.

Authors:  F Buseyne; M L Chaix; C Rouzioux; S Blanche; Y Rivière
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Authors:  Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

5.  Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.

Authors:  L Deml; A Bojak; S Steck; M Graf; J Wild; R Schirmbeck; H Wolf; R Wagner
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation.

Authors:  Mark J Geels; Sheri A Dubey; Kiersten Anderson; Elly Baan; Margreet Bakker; Georgios Pollakis; William A Paxton; John W Shiver; Jaap Goudsmit
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa.

Authors:  L Dorrell; T Dong; G S Ogg; S Lister; S McAdam; T Rostron; C Conlon; A J McMichael; S L Rowland-Jones
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Authors:  Kimberly Ritola; Christopher D Pilcher; Susan A Fiscus; Noah G Hoffman; Julie A E Nelson; Kathryn M Kitrinos; Charles B Hicks; Joseph J Eron; Ronald Swanstrom
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 gag-specific mucosal immunity after oral immunization with papillomavirus pseudoviruses encoding gag.

Authors:  Hongtao Zhang; Raja Fayad; Xilin Wang; Daniel Quinn; Liang Qiao
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  Functional properties and epitope characteristics of T-cells recognizing natural HIV-1 variants.

Authors:  U Malhotra; J Nolin; H Horton; F Li; L Corey; J I Mullins; M J McElrath
Journal:  Vaccine       Date:  2009-09-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.